U.S. oncologists, aware that patients are paying more of the costs of expensive cancer drugs, are increasingly declining to prescribe medicines that have scant or no effect, even as a last resort. At least half a dozen drugs, including colon cancer treatments Cyramza, from Eli Lilly & Co, and Stivarga, sold by Bayer AG, aren’t […]

ANN ARBOR, Mich. — Esperion Therapeutics, Inc. (ESPR)’s stock plummeted nearly 35 percent this morning after the company announced it will separately assess patients with statin intolerance following Phase II results. Esperion said it plans to conduct multiple Phase III clinical trials to “separately evaluate patients with statin intolerance, as well as patients who are […]

A new drug in early development cuts cholesterol as much as two potent injections recently cleared for sale but lasts much longer, meaning it may need to be given only every three to six months, initial findings suggest. Results with Alnylam Pharmaceuticals and Medicines Co’s experimental product ALN-PCSsc highlight the competition for a market tipped […]

Novo Nordisk (NVO), headquartered in Copenhagen, Denmark, announced yesterday that it will buy Calibrium LLC and MB2 LLC, two private biopharma companies based in Indiana.   Calibrium, located in Carmel, Ind., focuses on developing drug candidates for diabetes and related metabolic diseases. It was co-founded by Fritz French, the company’s chief executive officer, and Richard […]

Boston-based Intarcia Therapeutics, Inc., announced yesterday positive results from its Phase III Freedom-2 clinical trial comparing its late-stage ITCA 650 to Merck & Co. (MRK)’s Januvia for Type 2 diabetes.   The real news here is that ITCA 650 is a new type of diabetes treatment. It is a GLP-1 receptor agonist that utilizes a […]

YONKERS, NY–(Marketwired – Aug 17, 2015) – ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CF-301, the first […]

AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related Antibodies CAMBRIDGE, Mass.–(BUSINESS WIRE)   AVEO Oncology (AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including […]

THOUSAND OAKS, Calif., July 16, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of BLINCYTO® (blinatumomab) in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL). The investigational study showed blinatumomab monotherapy induced a complete remission […]

SAN DIEGO, July 9, 2015 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of ‘first-in-class’ small molecules against targets that have eluded the pharmaceutical industry to date and which may address […]